Key Documents

View All Documentation

C0737

Cilostazol

Name: Cilostazol
Brand: SIGMA

≥98% (HPLC), Phosphodiesterase III (PDE3) inhibitor, powder

Synonym(s):

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₀H₂₇N₅O₂

CAS Number:

73963-72-1

Molecular Weight:

369.46

UNSPSC Code:

41106305

PubChem Substance ID:

24278291

NACRES:

NA.77

MDL number:

MFCD00866780

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Cilostazol, ≥98% (HPLC), powder

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

off-white

solubility

DMSO: 10 mg/mL, clear

originator

Otsuka Pharma

SMILES string

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChI key

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Gene Information

human ... PDE3A(5139), PDE3B(5140)

Description

General description

Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.

Application

Cilostazol has been used:

to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
to induce adenosine triphosphate (ATP) release in white adipocytes

Biochem/physiol Actions

Phosphodiesterase III (PDE3) inhibitor

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Still not finding the right product?

Explore all of our products under Cilostazol

pictograms

GHS08

signalword

Warning

hcodes

H361d

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

042K4704

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

Dawson DL, et al.

Circulation, 98(7), 678-686 (1998)

Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells

Munoz B, et al.

European Journal of Pharmacology, 616(1-3), 22-30 (2009)

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

Money SR, et al.

Journal of Vascular Surgery, 27(2), 267-275 (1998)

View All Related Papers

Global Trade Item Number

SKU	GTIN
C0737-10MG	04061833451540
C0737-50MG	04061832897585